{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:46:55Z","timestamp":1761126415338,"version":"build-2065373602"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,1,12]],"date-time":"2004-01-12T00:00:00Z","timestamp":1073865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Optimal treatment of human immunodeficiency virus (HIV)\u2010associated non\u2010Hodgkin lymphoma (NHL) has yet to be defined, because chemotherapy could exacerbate immunodeficiency, with subsequent adverse effects for patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The authors investigated the feasibility of an intensive chemotherapy regimen for HIV\u2010associated NHL. Thirty\u2010eight patients were treated with a first course of cyclophosphamide (Cy), vincristine, and prednisone; followed by 3 courses of high\u2010dose Cy (2000 mg\/m<jats:sup>2<\/jats:sup>), doxorubicin (Doxo; 50 mg\/m<jats:sup>2<\/jats:sup>), vincristine, and prednisone (modified high\u2010dose CHOP); 1 course of high\u2010dose methotrexate (MTX; 8000 mg\/m<jats:sup>2<\/jats:sup>); and 1 course of high\u2010dose cytarabine (8000 mg\/m<jats:sup>2<\/jats:sup>). Radiotherapy was added to the treatment regimen for patients with bulky disease or residual tumor. Chemotherapy was administered in conjunction with granulocyte\u2013colony\u2010stimulating factor and antiretroviral therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Patients received 91.5%, 93%, 66%, and 63% of the scheduled doses of Cy, Doxo, MTX, and cytarabine, respectively. The complete response rate was 60.5%, with a total response rate of 79%. The 40\u2010month overall survival rate was 43%, the disease\u2010free survival rate was 65%, and the recurrence\u2010free survival rate was 39%. Both an International Prognostic Index score of 0 or 1 and Burkitt\u2010type histology had positive effects on survival, whereas CD4\u2010positive lymphocyte counts, viral burden, and previous highly active antiretroviral therapy did not. CD4\u2010positive T lymphocyte levels decreased from 0.197 \u00b1 0.156 \u00d710<jats:sup>9<\/jats:sup>\/L before treatment to 0.152 \u00b1 0.1 \u00d710<jats:sup>9<\/jats:sup>\/L at 6 months after the end of treatment. A decrease in viral load, from 380,000 \u00b1 785,000 copies\/mL before treatment to 25,000 \u00b1 43,000 copies\/mL at 6 months after the end of treatment, also was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The results of the current study indicate that intensive chemotherapy is effective and tolerable for patients with HIV\u2010associated NHL. Cancer 2004;100:667\u201376. \u00a9 2004 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20019","type":"journal-article","created":{"date-parts":[[2004,2,5]],"date-time":"2004-02-05T05:00:32Z","timestamp":1075957232000},"page":"667-676","source":"Crossref","is-referenced-by-count":12,"title":["Intensive sequential chemotherapy with hematopoietic growth factor support for non\u2010Hodgkin lymphoma in patients infected with the human immunodeficiency virus"],"prefix":"10.1002","volume":"100","author":[{"given":"R\u00e9gis T.","family":"Costello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hac\u00e8ne","family":"Zerazhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Marc Schiano","family":"de Colella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Alzieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Poizot\u2010Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolande","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie\u2010Jeanne","family":"Bardou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Xerri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Olive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meyer","family":"Nezri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rard","family":"Lepeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Albert","family":"Gastaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,2,3]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-60162-0_29"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106073442306"},{"issue":"1","key":"e_1_2_5_4_2","first-page":"27","article-title":"AIDS\u2010associated non\u2010Hodgkin's lymphoma in the era of highly active antiretroviral therapy","volume":"21","author":"Grulich AE","year":"1999","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"1","key":"e_1_2_5_5_2","first-page":"23","article-title":"Combination antiretroviral therapy and incidence of AIDS\u2010related malignancies","volume":"21","author":"Buchbinder SP","year":"1999","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"1","key":"e_1_2_5_6_2","first-page":"18","article-title":"Effect of highly active antiretroviral therapy on the incidence of HIV\u2010associated malignancies at an urban medical center","volume":"21","author":"Sparano JA","year":"1999","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"1","key":"e_1_2_5_7_2","first-page":"11","article-title":"Effect of antiretroviral therapy on recent trends in selected cancers among HIV\u2010infected persons","volume":"21","author":"Jones JL","year":"1999","journal-title":"J Acquir Immune Defic Syndr."},{"key":"e_1_2_5_8_2","first-page":"529","article-title":"Epidemiology of non\u2010Hodgkin's lymphoma: recent data","volume":"86","author":"Chassagne\u2010Clement C","year":"1999","journal-title":"Bull Cancer."},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2339"},{"issue":"1","key":"e_1_2_5_10_2","first-page":"34","article-title":"Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non\u2010Hodgkin's lymphomas among HIV\u20101\u2010infected individuals","volume":"21","author":"Jacobson LP","year":"1999","journal-title":"J Acquir Immune Defic Syndr."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051755"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2730"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03420050069041"},{"key":"e_1_2_5_14_2","first-page":"A7","article-title":"Novel combination chemotherapy for Hodgkin's disease (HD) in HIV\u2010infected individuals","volume":"10","author":"Kaplan L","year":"1991","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058108"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90259-R"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1691"},{"key":"e_1_2_5_18_2","first-page":"452","article-title":"Treatment of acquired immunodeficiency syndrome\u2010related lymphoma with a standard chemotherapy regimen","volume":"10","author":"Aviles A","year":"1999","journal-title":"Ann Hematol."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706053362304"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.9.1322"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.11.3026"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01422.x"},{"key":"e_1_2_5_23_2","first-page":"1195","article-title":"Autologous bone marrow transplantation in relapsed HIV\u2010related non\u2010Hodgkin's lymphoma","volume":"18","author":"Gabarre J","year":"1996","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-12-973"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401444"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.5.1722"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2171"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211053271903"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"e_1_2_5_30_2","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.1995.13.12.2916","article-title":"High\u2010dose CHOP as initial therapy for patients with poor\u2010prognostic aggressive non\u2010Hodgkin's lymphoma: a dose\u2010finding pilot study","volume":"13","author":"Shipp MA","year":"1999","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702080"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.6.847"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.32.2.292-300.1994"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.8.1018"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.6.963"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890115)63:2<228::AID-CNCR2820630204>3.0.CO;2-3"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162402"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10365"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010565"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02041-9"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00024"},{"key":"e_1_2_5_43_2","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study","volume":"92","author":"Coiffier B","year":"1998","journal-title":"Blood."},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409049677"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.6.929"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922299310917"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200182"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20019","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:14:33Z","timestamp":1760264073000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,3]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,2,15]]}},"alternative-id":["10.1002\/cncr.20019"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20019","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2004,2,3]]}}}